Skip to content

Optilene® Suture Material for Dermal Sutures

Assessment of Optilene® Suture Material for Skin Closure (Dermal Sutures). A Prospective Single-arm Observational Study in Daily Practice

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05240248
Acronym
OPTIDERMAL
Enrollment
172
Registered
2022-02-15
Start date
2022-06-22
Completion date
2023-07-23
Last updated
2024-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incision, Laceration

Brief summary

In this non-interventional study, Optilene® suture will be evaluated for skin closure in adult patients.

Detailed description

The study is designed as a prospective, unicentric and single-arm observational study to evaluate Optilene® suture material for skin closure. The product under investigation will be used in routine clinical practice and according to the Instructions for Use (IFU). After operation the investigator will examine the patients at discharge, at 10±5 days after surgery (removal of the suture) and 30±10 days postoperatively.

Interventions

None listed

Sponsors

B.Braun Surgical SA
CollaboratorINDUSTRY
Aesculap AG
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients undergoing skin closure using Optilene® suture material. * Small (0.5 cm - 10 cm) linear minimally contaminated incision/laceration in the trunk, neck or extremities (in the event that more than one incision is performed in the same patient, only one incision will be included). * Written informed consent.

Exclusion criteria

* Emergency surgery. * Transplant surgery. * Pregnancy. * Facial laceration or incision. * Visible dirt in the wound. * Non-linear shape. * Patient with limb ischemia. * Patient taking medication that might affect wound healing (i.e. cytotoxic antineoplastic and immunosuppressive agents, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), anticoagulants). * Patient with hypersensitivity or allergy to the suture material.

Design outcomes

Primary

MeasureTime frameDescription
Surgical Site Infection Rateat suture removal approximately 10±5 days postoperatively.A surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be superficial infections involving the skin only. Other surgical site infections are more serious and can involve tissues under the skin, organs, or implanted material.

Secondary

MeasureTime frameDescription
Wound dehiscence rateat discharge from hospital (up to 5 days postoperatively)Pathologic process consisting of a partial or complete disruption of the layers of a surgical wound.
Cumulative rate of Adverse Events during the study periodat discharge (up to 5 days postoperatively), at suture removal (approximately 10±5 days postoperatively) and at follow-up visit approximately 30±10 days postoperativelyfrequency of Tissue reaction, Inflammation, Seroma, Abscess formation, Hematoma, Granuloma, Bleeding, Necrosis and Irritation
Development of Cosmetic Outcomeat discharge (up to 5 days postoperatively), at suture removal (approximately 10±5 days postoperatively) and at follow-up visit approximately 30±10 days postoperativelyOverall patient and observer satisfaction with the scar using the Patient and Observer Scar Assessment Scale (POSAS). Cosmetic result and the scar will be evaluated by the patient and the physician. Patient will rate the cosmetic outcome in six categories (Pain, Itching, Color of scar, Stiffness of scar, thickness and irregularity of scar) on a 1 to 10 points scale each. The physician will use the Observer component, rating vascularization, pigmentation, thickness, relief and pliability of the scar on a 1 to 10 points scale each. The categories are added to a total POSAS score of 11 (minimum) to 110 points (maximum).
Surgical Site Infection Rateat discharge from hospital (up to 5 days postoperatively)A surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be superficial infections involving the skin only. Other surgical site infections are more serious and can involve tissues under the skin, organs, or implanted material.
Development of Satisfaction of the patient: Visual Analogue Scale (VAS)at suture removal (approximately 10±5 days postoperatively) and at follow-up visit approximately 30±10 days postoperativelyThis parameter will be noted using the Visual Analogue Scale (VAS) which state 0 at one end representing very poor and 100 at the opposite end representing excellent.
Duration of surgeryintraoperativelytime from cut to closure in minutes.
Handling of the suture materialintraoperativelyThe handling of the suture material is assessed using a questionnaire assessing the Knot security (The quality of a suture that allows it to be tied securely with a minimum number of throws per knot), the Knot pull tensile strength (strength of the thread while knotting), the Knot run down (Ease with which a knot can be slid down), the Tissue drag (Passage through the tissue), the Pliability (The quality of being easily to bent, flexibility) and the Overall opinion of the surgeon each with the 5 evaluation levels of 'excellent', 'very good', 'good', 'satisfied' and 'poor':.
Development of Pain: Visual Analogue Scale (VAS)at suture removal (approximately 10±5 days postoperatively) and at follow-up visit approximately 30±10 days postoperativelyThis parameter will be noted using the Visual Analogue Scale (VAS) which state 0 at one end representing no pain and 100 at the opposite end representing heavy pain.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026